IDEXX Laboratories (IDXX) vs Illumina (ILMN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Illumina (ILMN) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 170.6% versus a loss of 18.5%. Over five years, IDXX leads with a -19.2% price change compared with -33.7% for ILMN. IDEXX Laboratories is the larger company by market cap ($40.43 billion vs $39.95 billion), about 1.0 times the size.
On valuation, IDEXX Laboratories trades at a lower forward P/E (30.7x vs 43.2x for Illumina). IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus 19.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | ILMN |
|---|---|---|
| Share price | $513.14 | $264.57 |
| Market cap | $40.43B | $39.95B |
| 1-day change | +1.28% | -1.19% |
| YTD return | -24.15% | +101.72% |
| 1-year return | -18.54% | +170.58% |
| 5-year return | -19.21% | -33.65% |
| P/E ratio (TTM) | 36.06 | 49.36 |
| Forward P/E | 30.66 | 43.24 |
| EPS (TTM) | $14.23 | $5.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $4.34B |
| Revenue growth (YoY) | +10.42% | -0.66% |
| Net income (latest FY) | $1.06B | $850.00M |
| Gross margin | 61.80% | 66.08% |
| Operating margin | 31.60% | 18.58% |
| Net margin | 24.62% | 19.57% |
| 52-week high | $769.98 | $309.35 |
| 52-week low | $500.61 | $88.00 |
| Distance from 52-week high | -33.36% | -14.48% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +36.67% | -12.25% |
| Average volume | 553.95K | 2.69M |
| Shares outstanding | 78.78M | 151.00M |
| Employees | 11,000 | 8,600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ILMN has outperformed IDXX by 189.1 percentage points over the past year.
- Illumina trades at a higher earnings multiple (49.4x vs 36.1x trailing P/E).
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus 19.6 cents for Illumina.
- IDEXX Laboratories grew revenue faster in its latest fiscal year (+10.42% vs -0.66%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Health Care · Medical Specialities · 8,600 employees
IDXX vs ILMN FAQ
Which is bigger, IDEXX Laboratories or Illumina?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.43B compared with $39.95B for Illumina (ILMN).
Which stock has performed better over the past year, IDXX or ILMN?
ILMN returned +170.58% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IDXX or ILMN?
IDXX has the lower trailing P/E at 36.1, versus 49.4 for ILMN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are IDEXX Laboratories and Illumina in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for IDEXX Laboratories and Medical Specialities for Illumina.